title: Aberrant T helper 17 cells and related cytokines in bone marrow microenvironment of patients with acute myeloid leukemia.
abstract: In this study, we mainly investigate the role of Th17 cells, Th1 cells, and their related cytokines in the pathophysiology of AML. BM and PB were extracted from ND, CR, and relapsed-refractory AML patients and controls. Th subsets frequencies were examined by flow cytometry. BM plasma Th-associated cytokines levels were determined by ELISA. The frequencies of Th17 and Th1, and IFN-γ or TGF-β concentrations were significantly decreased in ND compared with CR patients or controls. Th17 percentage was significantly lower in BM than in PB for ND patients but was higher in BM for CR patients. However, in CR or relapsed-refractory patients, Th1 percentage in BM was higher than that in PB. Moreover, BM IL-17A level showed a decreased trend in ND patients. A significant elevation of plasma IL-6 level was found in ND compared with CR patients or controls. IL-17A showed the positive correlation with IL-6 concentration. And Th17 cells frequencies and TGF- β1 concentration were increased in BM from AML patients achieving CR after chemotherapy. Moreover, a significant decrease of BM plasma TGF- β1 level was found in M3 patients compared with the other subtypes. Our findings suggest that Th17 and related cytokines may be implicated in AML pathogenesis.
authors.affiliation: Department of Hematology, Qilu Hospital, Shandong University, 107 West Wenhua Road, Jinan 250012, China.
authors.forename: Tian
authors.initials: T
authors.lastname: Tian
authors.forename: Shuang
authors.initials: S
authors.lastname: Yu
authors.forename: Min
authors.initials: M
authors.lastname: Wang
authors.forename: Cunzhong
authors.initials: C
authors.lastname: Yuan
authors.forename: Hua
authors.initials: H
authors.lastname: Zhang
authors.forename: Chunyan
authors.initials: C
authors.lastname: Ji
authors.forename: Daoxin
authors.initials: D
authors.lastname: Ma
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001853:Bone Marrow / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood / Q000378:metabolism*; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D058504:Th17 Cells / Q000276:immunology* / Q000378:metabolism*; D016896:Treatment Outcome; D059016:Tumor Microenvironment / Q000276:immunology*; D055815:Young Adult
chemical_list: D016207:Cytokines
references.citation: Clin Exp Immunol. 2010 Aug;161(2):223-32
references.pmid: 20529084
references.citation: J Immunol. 2007 Jun 1;178(11):6730-3
references.pmid: 17513719
references.citation: Hum Immunol. 2012 Jun;73(6):629-35
references.pmid: 22537755
references.citation: Curr Rheumatol Rep. 2007 Dec;9(6):461-7
references.pmid: 18177599
references.citation: Nat Immunol. 2005 Nov;6(11):1133-41
references.pmid: 16200068
references.citation: Zhonghua Xue Ye Xue Za Zhi. 2010 Sep;31(9):617-20
references.pmid: 21122324
references.citation: J Exp Med. 2007 Jan 22;204(1):41-7
references.pmid: 17227914
references.citation: Nature. 2008 Jul 17;454(7202):350-2
references.pmid: 18469800
references.citation: Arthritis Rheum. 2007 Jul;56(7):2111-5
references.pmid: 17599728
references.citation: Lancet. 2006 Nov 25;368(9550):1894-907
references.pmid: 17126723
references.citation: Clin Chim Acta. 2011 May 12;412(11-12):894-900
references.pmid: 21255562
references.citation: J Exp Med. 2009 Jan 16;206(1):35-41
references.pmid: 19114665
references.citation: Inflamm Bowel Dis. 2008 Feb;14(2):204-12
references.pmid: 18022867
references.citation: Immunol Rev. 2008 Jun;223:87-113
references.pmid: 18613831
references.citation: Nat Immunol. 2012 Oct;13(10):991-9
references.pmid: 22961052
references.citation: Br J Haematol. 1976 Aug;33(4):451-8
references.pmid: 188440
references.citation: Immunity. 2006 Feb;24(2):179-89
references.pmid: 16473830
references.citation: Nature. 2006 May 11;441(7090):235-8
references.pmid: 16648838
references.citation: N Engl J Med. 1999 Sep 30;341(14):1051-62
references.pmid: 10502596
references.citation: Nat Med. 2007 Oct;13(10):1173-5
references.pmid: 17828272
references.citation: Clin Cancer Res. 2008 Jun 1;14(11):3254-61
references.pmid: 18519750
references.citation: Immunity. 2008 Apr;28(4):445-53
references.pmid: 18400187
references.citation: Nat Immunol. 2008 Jun;9(6):650-7
references.pmid: 18454150
references.citation: Nature. 2003 Feb 13;421(6924):744-8
references.pmid: 12610626
references.citation: Nat Immunol. 2008 Jun;9(6):641-9
references.pmid: 18454151
references.citation: Blood. 2009 Aug 6;114(6):1141-9
references.pmid: 19470694
references.citation: J Exp Med. 2003 Dec 15;198(12):1951-7
references.pmid: 14662908
references.citation: PLoS One. 2012;7(12):e51339
references.pmid: 23236476
references.citation: Mol Oncol. 2010 Aug;4(4):335-46
references.pmid: 20471335
references.citation: Nature. 2006 May 11;441(7090):231-4
references.pmid: 16648837
references.citation: Cancer Sci. 2010 Sep;101(9):1947-54
references.pmid: 20550524
references.citation: Clin Exp Immunol. 2009 Nov;158(2):199-204
references.pmid: 19737137
references.citation: J Clin Oncol. 1990 May;8(5):813-9
references.pmid: 2185339
references.citation: Nat Immunol. 2007 Sep;8(9):942-9
references.pmid: 17676045
references.citation: J Cell Biochem Suppl. 2002;38:88-95
references.pmid: 12046855
references.citation: J Immunol. 1993 Mar 15;150(6):2418-30
references.pmid: 8383719
references.citation: Nat Immunol. 2005 Nov;6(11):1123-32
references.pmid: 16200070
references.citation: Cell. 2006 Sep 22;126(6):1121-33
references.pmid: 16990136